The recent discovery of more potent and selective PDK1 inhibitors [34, 35] and Ron inhibitors [36, 37], and their forthcoming tests in tumor models will be instrumental to understand the significance of sfRon and PDK1 inhibition in high-grade serous ovarian cancer. Here, PDK1 is linked to ovarian serous adenocarcinoma.